Wednesday, July 8, 2026

Drug profile · INN

vincristine sulfate

vincristine sulfate (VINCRISTINE SULFATE) is a tubulin inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 20
News articles 0
Drug details — vincristine sulfate
US status
approved
Class
Route
INJECTION
Patents
0
Programs
20
Data quality
0.89

Quick answer

vincristine sulfate (VINCRISTINE SULFATE) is a tubulin inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN vincristine sulfate
Brand VINCRISTINE SULFATE
Mechanism Tubulin inhibitor
Target Tubulin
Route INJECTION
Formulation INJECTABLE, LIPOSOMAL

Mechanism of action

Tubulin inhibitor

Primary target: Tubulin

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. 2019/2894 Phase 3 · George Institute for · Patients with High Risk Neuroblastoma
  2. 20190360 Phase 3 · Amgen · Newly diagnosed Philadelphia-negative B-cell precursor Acute
  3. CA073-1003 Phase 3 · Celgene · Relapsed/Refractory Follicular Lymphoma
  4. CA073-1020 Phase 3 · Celgene · High-risk Large B-cell Lymphoma
  5. D7402C00001 Phase 3 · AstraZeneca · Large B-cell Lymphoma
  6. HQP1351AG301 Phase 3 · Anaxis Pharma · Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymph
  7. KT-US-473-0133 Phase 3 · Anaxis Pharma · Relapsed/Refractory Follicular Lymphoma
  8. M20-621 Phase 3 · AbbVie Deutschland GmbH · Diffuse Large B-Cell Lymphoma (DLBCL)

Related & competitor drugs

  1. brentuximab vedotin Antineoplastic and immunomodulating agents (L01)
  2. cabazitaxel Antineoplastic and immunomodulating agents (L01)
  3. colchicine Musculo-skeletal system (M04)
  4. docetaxel Antineoplastic and immunomodulating agents (L01)
  5. paclitaxel Antineoplastic and immunomodulating agents (L01)
  6. vinorelbine tartrate Tubulin inhibitor

Frequently asked questions

What is vincristine sulfate?

vincristine sulfate (VINCRISTINE SULFATE) is a tubulin inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for vincristine sulfate?

VINCRISTINE SULFATE is a marketed brand name for vincristine sulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of vincristine sulfate?

vincristine sulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.